Diferansiye tiroid karsinomlu hastalarda I-131 tedavisinin etkinliği

Amaç: Bu çalışmanın amacı diferansiye tiroid karsinomlu hastalarda cerrahi sonrası radyoaktif 1-131 tedavisinin etkinliğini değerlendirmektir. Yöntem: Hacettepe Üniversitesi Tıp Fakültesine başvuran diferansiye tiroid karsinomlu 95 hastada postoperatif tanısal tüm vücut 1-131 taraması yapıldı, ardından terapötik dozda radyoaktif iyot verildi. 95 hastanın 41'inde tiroid yatağında, 36'smda lenf nodlarında, 18'inde mediasten, akciğer ve/veya kemikte radyoiyot tutulumu vardı. Bulgular: 82 hastada (% 86) 100-200 mCi arasındaki ilk doz 1-131 ile başarılı ablasyon sağlanırken, 13 hastada ikinci veya üçüncü dozla ablasyon yapıldı. Sonuç: Diferansiye tiroid karsinomlu hastalarda total tiroidektominin ardından ablatif radyoaktif iyot tedavisi verilmesinin en uygun tedavi yöntemi olduğu sonucuna varıldı.

Effectiveness of I-131 treatment in patients with differentiated thyroid carcinoma

Objective: The purpose of this study was to evaluate the efficacy of postsurgical radioactive 1-131 therapy in patients with differentiated thyroid carcinoma. Methods: in ninety-five patients with differentiated thyroid carcinoma who were referred to Hacettepe University Medical Center, postoperative diagnostic total body 1-131 scan was done, subsequently patients received therapeutic radioactive iodine. Of 95 patients, 41 were with radioiodine uptake confined to the thyroid bed, 36 had distant uptake in the lymph nodes and 18 had distant metastases in the mediastinum, lung and/or bone. Results: A successful ablation was achieved in 82 patients (86%) with the first dose of 1-131 ranging from 100 to 200 mCi, while 13 patients had ablation with a second or third dose. Conclusion: Total thyroidectomy is associated with better ablation and is recommended when feasible, for differentiated thyroid cancer, followed by ablative 1-131 therapy.

Kaynakça

De Ellis RA. The endocrine system. In: Cotron RS, Kumar V, Robbins SL, editor. Pathologic basis of disease. 4th ed. Philadelphia: WB Saunders; 1989. p.1230-40.

Mazzafferri EL. Textbook of endocrinology. 3rd ed. New York: New HydePark; 1986. p. 254-69.

Hurley JR, Becker DV. The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weisman HS, editor. Nuclear Medicine Annual. New York: New York Raven; 1983. p. 329-34.

Mazzafferri EL, Young RL. Papillary thyroid carcinoma: A 10 year follow-up of the impact of therapy in 576 patients. Am J Med 1981;70:511-8.

Boring CC, Squires TS, Tong T. Cancer statistics, 1991. Cancer J Clin 1991;41:19-36.

Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S. An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947-1984: Experience at University of Michigan. J Nucl Med 1984;25:1287-93.

Kuni CC, Kleingensmith WC 3rd. Failure of low doses of I-131 to ablate residual thyroid tissue following surgery of thyroid cancer. Radiology 1980;137:773-4.

Degroot LJ, Reilly M. Comparison of 30 and 50 mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1982;96:51-3.

Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991;32:252-4.

Bender JM, Dworkin HJ. Iodine-131 as an oncology agent. J Nucl Med Technol 1993;21:140-50.

Leeper RD. Thyroid cancer. Med Clin North Am 1995;69:1079-96.

Maxon HR 3rd, Englaro EE, Thomas SR, Hertzbergus, Hinnefeld JD, Chen LS, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative approach: Outcome and validation in 85 patients. J Nucl Med 1992;33:1132-6.

Dworkin HJ, Meier DA, Kaplan M. Advances in the management of patients with thyroid disease. Semin Nucl Med 1995;25:205-20.

Samaan NA, Maheshwari YK, Nadeer S, Hill CS Jr, Schultz PN, Haynie TP, et al. Impact of therapy for differentiated carcinoma of the thyroid: An analysis of 706 cases. J Clin Endorinol Metab 1983;56:1131-8.

Casano C, Bashieri I, Bashieri L. Follow-up of 188 cases of thyroid carcinoma after combined surgical and radioiodine treatment. In: Young S, Inman DR, editor. London: Academic Press; 1968. p. 143.

Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE. Treatment of thyroid cancer: Death rates after surgery followed by sodium iodine I-131. JAMA 1970;214:1437-42.

Ley PB, Roberts JW, Symmonds RE Jr, Hendricks JC, Synder SK, Frazee RC, et al. Safety and efficacy of total thyroidectomy for differentiated thyroid carcinoma: A 20-year review. Am Surg 1993;59:110-4.

Duren M, Yavuz N, Bukey Y, Ozyegin MA, Gundogdu S, Acbay O, et al. Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region. World J Surg 2000;24:1290-4.

7. Asya ve Okyanusya Nükleer Tıp ve Biyoloji Kongresi ve 4. Uluslararası Nükleer Onkoloji Kongresinde sunulmuştur.

Kaynak Göster